碱性磷酸酶在临床相关疾病认知障碍中的研究
Research on Alkaline Phosphatase in Cognitive Impairment of Clinical Related Diseases
DOI: 10.12677/ACM.2023.1351195, PDF, HTML, XML, 下载: 274  浏览: 491 
作者: 李 卓:青海大学研究生院,青海 西宁;刘 冀:青海大学附属医院老年医学科,青海 西宁
关键词: 认知障碍碱性磷酸酶临床相关疾病Cognitive Impairment Alkaline Phosphatase Clinically Relevant Disease
摘要: 认知障碍的发病率随全球人口老龄化呈逐年升高趋势,其最严重可发展为痴呆,给个人及家庭带来了沉重的负担。碱性磷酸酶(ALP)作为人体内众多酶中的一种,发挥着强大的作用,同时它也是目前免疫诊断试剂产品最常用的标记酶之一,拥有稳定性高、灵敏度高等诸多优点。而近些年来,大量研究显示,ALP水平在认知障碍中也存在显著增高。本文就ALP的结构及生物学特性以及在临床相关性疾病认知障碍中作用的研究作一综述。
Abstract: The incidence of cognitive disorders increases year by year with the aging of the global population, and the most serious can develop into dementia, which brings a heavy burden to individuals and families. Alkaline phosphatase (ALP), as one of the many enzymes in human body, plays a powerful role. At the same time, ALP is also one of the most commonly used marker enzymes in immunodi-agnostic reagent products. It has many advantages, such as high stability and high sensitivity. In recent years, a large number of studies have shown that ALP level is also significantly increased in cognitive impairment. This review reviews the structure and biological characteristics of ALP and its role in cognitive impairment in clinically related diseases.
文章引用:李卓, 刘冀. 碱性磷酸酶在临床相关疾病认知障碍中的研究[J]. 临床医学进展, 2023, 13(5): 8541-8546. https://doi.org/10.12677/ACM.2023.1351195

1. 引言

认知障碍(CI)的发生率随着现代经济的发展和人口的老龄化愈来愈高,逐渐成为很多家庭不可逆的负担,同时严重影响到了患者的日常生活,其危害不容小觑 [1] 。近年来,对于认知障碍的研究层出不穷。碱性磷酸酶(alkaline phosphstase, ALP)是一种常见的水解酶,广泛地存在于多种动物和微生物体内。AlP作为一种血管钙化调节剂,与炎症反应、动脉粥样硬化、血管稳态等密切相关。既往多在骨骼系统、肝胆系统、内分泌系统、肾脏等相关疾病的临床应用中发挥其作用。近年来有研究表示血清ALP与认知障碍也有密切关系,ALP水平升高可能是认知功能障碍发生的危险因素;且血浆中ALP水平增加与认知呈负相关;ALP的动态监测对认知功能障碍的发生、发展、预后提供了有效的依据。此外,炎症作为临床上常见病理过程,是糖尿病、阿尔茨海默症、COPD及OSAHS、脑卒中后伴发血管性认知功能障碍等临床常见慢性疾病的病理基础,同时在上述疾病伴发认知障碍的发生发展中也发挥了重要的作用 [2] 。现将ALP的结构、生物学特性以及在临床相关性疾病认知障碍中作用的研究综述如下。

2. ALP的结构及生物学特性

ALP是一种广泛分布在各种体液中的细胞表面蛋白,最早是在1923年由Robison发现并分离 [3] 。ALP作为人体中的一种由多基因编码的膜金属蛋白结合酶,可以在碱性条件下催化单磷酸酯的水解反应,产生无机磷酸及相应的酚、醇或者糖类,也可以催化磷酸基团的转移反应 [4] 。ALP在人体中以四种同工酶的形式存在,分别为肠型ALP(IAP)、胎盘型ALP(PLAP)、生殖细胞型ALP (GCAP)和组织非特异型ALP (TNAP),前三种同工酶在其命名的组织中表达,并且每一种通过人类独特的同源基因位点:ALPI、ALPP、ALPPL2和ALPL所编码 [5] [6] [7] [8] [9] 。TNAP主要存在于骨骼、肾脏以及肝脏中,其中骨特异性ALP (BALP)在体内主要经肝脏代谢,不受肾功能的影响,BAlP的半衰期为1~2天,可以在56℃下25分钟内灭活。BALP有B1、B2、B/I和B1x四个亚型,其中前三个存在于人体血清中,最后一个只存在于部分CKD患者体内,还未于健康者体内检测到。TNAP除了表达于上述部位中,还在脑的内皮细胞、神经元细胞和神经突触部位表达。ALP在血清中作为可溶性蛋白存在,在细胞外间隙作为囊泡相关蛋白,当磷脂酰肌醇磷脂酶裂解时,被GPI锚定的ALP从质膜上脱落,进入血液中以可溶性形式存在 [10] 。越来越多的证据证明了ALP异常提示与骨骼系统、肾脏系统、肠道系统、神经系统等疾病的发生发展有明显关系。

3. ALP与临床相关疾病

3.1. 2型糖尿病

2型糖尿病(T2DM)是一组由于胰岛素分泌不足和或胰岛素抵抗所引起以慢性血糖升高为主要临床特征的代谢性疾病,临床特点表现为病程长、发生率高等特点。长时间的代谢紊乱可导致全身多种器官多种系统受累,包括眼、心血管、肾脏、四肢等重要的组织器官,使其发生进行性病变、功能障碍甚至衰竭。严重时可导致急性严重代谢紊乱,危及生命。糖尿病的病因及机制复杂且未完全阐明,可能遗传因素、环境因素及免疫因素共同参与其发病。有研究表明,T2DM患者中存在认知障碍的人群远多于血糖正常者,T2DM应该被认为是轻度认知障碍的危险因素 [11] 。一项大样本Meta分析显示,糖尿病使认知功能障碍的风险增加了1.25~1.91倍,糖尿病前期的患者患痴呆症的风险也更高 [12] 。认知障碍会降低患者的生活质量和预后,认知障碍现作为T2DM的并发症之一,往往不被重视,目前也没有预防、诊断及治疗T2DM患者认知障碍的标准化建议 [13] 。另有一项研究显示 [14] ,2型糖尿病患者除HDL-C水平明显低于健康对照组,ALP、FPS、FINS、HOMA-IR、TC、TG、LDL-C水平均高于健康对照组,ALP与BMI、WHR、TC、TG、LDL-C、FPS、FINS、HOMA-IR均呈现明显正相关。提示T2DM患者表现胰岛素抵抗和高胰岛素血症,并伴有高脂血症和肝脏功能损害。由此说明糖尿病患者由于胰岛素分泌不足或胰岛素抵抗,造成糖代谢异常,同时影响脂类代谢,从而导致其在肝内沉积,最终形成脂肪肝,从而使肝脏受损引起ALP升高 [15] 。还有研究显示,ALP为脑小血管病患者发生认知障碍的独立因素 [16] 。因此,高血糖水平愈高,导致ALP水平愈高,认知障碍的发生率也越高,形成一种恶性循环。

3.2. 肾性骨病

肾性骨病(CKD-MBD)是由慢性肾脏病引起的钙、磷、维生素D、甲状旁腺激素等代谢异常引起的系统性疾病,包括以下任一项或多项:1) 钙、磷、甲状旁腺激素或维生素D代谢异常;2) 骨的转换、矿化、容积、线性生长或强度异常;3) 血管或其他软组织钙化 [17] 。根据骨骼转换速率可将肾性骨病分为四种类型:高转换型骨病、低转换型骨病、混合性骨病和β2-微球蛋白淀粉样变性骨关节病。以前人们一直认为高转换型骨病为主要类型,然而现如今有越来越多的证据证明低转换型骨病是普遍存在的 [18] 。骨活检是诊断和评估CKD-MBD的金标准,但是由于其具有创伤性、价格昂贵且进行骨组织形态学检测的机构数量非常有限等局限性,使它在临床上的应用受到制约,而KDIGO指南推荐用血清骨特异性碱性磷酸酶(bone-special alkaline phosphatase, BAP)的水平来评估CKD患者的骨代谢紊乱 [19] 。有研究发现 [20] 血液透析患者血清中BAP浓度 > 20 ng/ml时可以排除低转换型骨病。Bervoet等 [21] 发现在血透患者体内,当BAP ≤ 10 ng/ml时,患者患有低转换型骨病可能性大。同时BAP对于CKD患者的预后评估也具有很大意义,越来越多证据证明患者BAP水平与CKD患者患心血管疾病的发生率息息相关。ALP除了可见于骨骼中,亦可见于脑内皮细胞、神经细胞突触接触处等部位 [22] ,参与调控中枢神经系统等损伤 [23] 。作为ALP同工酶之一BNP升高时,亦会使认知功能损伤发生率明显升高,随着CKD-MBD病情加重,认知障碍的发生发展也会继续进行。

3.3. 神经系统疾病

脑小血管病(CSVD)系脑内小动脉、微动脉、毛细血管和小静脉发生病变导致腔隙性梗死(LI)、腔隙(lacune)、脑白质病变(WML)、血管周围间隙扩大及脑微出血(CMB)等的疾病总称 [24] 。其临床表现主要有中风、认知功能下降、痴呆、精神异常、步态异常和尿失禁 [25] 。CSVD是老年人发生认知功能下降的主要原因之一。临床研究发现,ALP与脑小血管病密切相关。血清ALP水平升高可能是缺血性脑白质脱髓鞘的危险因素 [26] 、也是脑小血管病的危险因素 [27] 。ALP参与γ-氨基丁酸的代谢,而且在神经元突触可塑性和皮质功能方面发挥着作用 [28] 。另研究显示,ALP在阿尔兹海默症(AD)患者血浆中和大脑中均增加,血浆中ALP的升高反应神经元中ALP的改变。血浆中ALP增加与AD的认知功能呈负相关 [29] 。需要明确的是,ALP与年龄无相关性。皮质下缺血性血管病患者血清ALP水平显著升高,其升高水平与皮质下缺血性脑血管病患者认知损害呈正相关,尤其是脑白质疏松较为严重者 [30] 。可见,ALP与认知功能下降的发生发展有着密切的关系。

3.4. 心血管疾病

在一项Meta分析中,Li等人从Embase和PubMed中搜索临床试验,从开始到2013年12月,使用关键词“ALP”、“磷酸盐”、“CVD”、“死亡率”等,最后有24个试验,共计147,634名患者纳入这项研究。进行了剂量反应和半参数Meta分析。而后他们发现,ALP水平与心血管疾病死亡具有相关性,然而,与非致死性心血管事件或冠心病之间的关系在调整混杂因素后变得不显著 [31] 。另一研究报告了血清ALP水平与CVD之间的独立相关 [32] 。既往研究提示高ALP水平与冠脉钙化、动脉粥样硬化密切相关,可导致动脉粥样硬化疾病,并且这种关联独立于其他传统心血管危险因素 [33] 。Ndrepepa Gjin等人通过对2134例PCI术后的急性冠脉综合征(acute coronary syndrome, ACS)患者随访后发现血清高ALP水平与冠状动脉钙化程度密切相关,且是行PCI术的ACS患者预后的独立预测因子 [34] 。有研究显示,心血管疾病患者会出现不同程度的认知功能障碍,这不仅出现延误治疗的情况,更严重影响他们的活动能力和生活质量 [35] 。心血管疾病患者会出现脑血流量减少,血液黏度增加,致使红细胞携氧能力降低,导致慢性脑缺氧、脑动脉粥样硬化所致的神经纤维脱髓鞘等情况的发生,最终导致认知功能障碍的发生与发展 [36] 。以上研究均可以证实ALP与心血管疾病患者发生认知障碍的发生、发展及预后存在一定意义。

3.5. 恶性肿瘤

恶性肿瘤是造成人类死亡的重要原因之一,是多种因素长期共同作用引发的基因异常疾病,其诊断常常基于病理检查。ALP通常用于检测胆管系统的阻塞,在一些肝源性的疾病,如胆结石、酒精滥用、肝炎、原发性胆汁肝硬化、原发性肝或胆肿瘤、肝转移性肿瘤等中看ALP可升高 [37] 。有研究表明,ALP可作为食管鳞状细胞癌、肝细胞癌、鼻咽癌和胰腺癌的预后标记 [38] [39] [40] [41] 。认知障碍是恶性肿瘤及其治疗的常见副作用,Gamal Kotb等人的研究表明,化疗引起的认知障碍是是恶性肿瘤患者化疗后的一个主要问题,可影响患者的生存质量 [42] 。综上所述,ALP参与了恶性肿瘤的发生发展以及化疗后引起认知障碍的过程。

4. 总结ALP

与2型糖尿病、肾性骨病、脑小血管病及阿尔兹海默症、心血管疾病、恶性肿瘤及其治疗后伴发认知障碍等相关疾病有密切关系,可通过不同形式及途径在疾病发生发展中发挥其作用,目前ALP在临床认知障碍相关疾病的应用中取得了一定进展,但其在相关认知障碍疾病中的具体机制尚不明确,有待进一步的研究。ALP与认知障碍等神经相关疾病的形成存在潜在联系可能作为认知障碍相关疾病治疗的研究方向,并可能成为临床治疗认知障碍的潜在新靶点。

参考文献

[1] 任盈盈. 高甘油三酯腰围表型与老年认知障碍的相关研究[D]: [硕士学位论文]. 济宁: 济宁医学院, 2022.
https://doi.org/10.27856/d.cnki.gjnyx.2022.000026
[2] Kealy, J., et al. (2020) Acute Inflammation Alters Brain Energy Metabolism in Mice and Humans: Role in Suppressed Spontaneous Activity, Impaired Cognition, and Delirium. The Journal of Neuroscience, 40, 5681-5696.
https://doi.org/10.1523/JNEUROSCI.2876-19.2020
[3] Robison, R. (21923) The Possible Significance of Hex-osephosphoric Esters in Ossification. Biochemical Journal, 17, 286-293.
https://doi.org/10.1042/bj0170286
[4] 肖婷. 碱性磷酸酶与脑小血管病患者认知功能的相关性研究[D]: [硕士学位论文]. 南昌: 南昌大学, 2020.
https://doi.org/10.27232/d.cnki.gnchu.2020.000108
[5] Millán, J.L. (1986) Molecular Cloning and Sequence Analysis of Human Placental Alkaline Phosphatase. The Journal of Biological Chemistry, 261, 3112-3115.
https://doi.org/10.1016/S0021-9258(17)35755-1
[6] Weiss, M.J., et al. (1986) Isolation and Characterization of a cDNA Encoding a Human Liver/Bone/Kidney-Type Alkaline Phosphatase. Proceedings of the National Academy of Sci-ences of the United States of America, 83, 7182-7186.
https://doi.org/10.1073/pnas.83.19.7182
[7] Millán, J.L. and Manes, T. (1988) Seminoma-Derived Nagao Iso-zyme Is Encoded by a Germ-Cell Alkaline Phosphatase Gene. Proceedings of the National Academy of Sciences of the United States of America, 85, 3024-3028.
https://doi.org/10.1073/pnas.85.9.3024
[8] Berger, J., Garattini, E., Hua, J.C. and Udenfriend, S. (1987) Cloning and Sequencing of Human Intestinal Alkaline Phosphatase cDNA. Proceedings of the National Academy of Sciences of the United States of America, 84, 695-698.
https://doi.org/10.1073/pnas.84.3.695
[9] Buchet, R., Millán, J.L. and Magne, D. (2013) Multisystemic Functions of Alkaline Phosphatases. In: Millán, J., Ed., Phosphatase Modulators. Methods in Molecular Biology, Vol. 1053, Hu-mana Press, Totowa, 27-51.
https://doi.org/10.1007/978-1-62703-562-0_3
[10] Low, M.G. (1987) Biochemistry of the Glyco-syl-Phosphatidylinositol Membrane Protein Anchors. Biochemical Journal, 244, 1-13.
https://doi.org/10.1042/bj2440001
[11] Gao, Y., et al. (2015) The Characteristic of Cognitive Function in Type 2 Diabetes Mellitus. Diabetes Research and Clinical Practice, 109, 299-305.
https://doi.org/10.1016/j.diabres.2015.05.019
[12] Xue, M., et al. (2019) Diabetes Mellitus and Risks of Cognitive Impairment and Dementia: A Systematic Review and Meta-Analysis of 144 Prospective Studies. Ageing Research Re-views, 55, Article ID: 100944.
https://doi.org/10.1016/j.arr.2019.100944
[13] Simó, R., Ciudin, A., Simó-Servat, O. and Hernández, C. (2017) Cognitive Impairment and Dementia: A New Emerging Complication of Type 2 Diabetes—The Diabetologist’s Perspec-tive. Acta Diabetologica, 54, 417-424.
https://doi.org/10.1007/s00592-017-0970-5
[14] 孙琦. 西宁地区107例糖尿病患者血清碱性磷酸酶检测分析[J]. 检验医学与临床, 2010, 7(20): 2301-2302.
[15] 郭蓉, 吴立红, 周小芳, 王吉玉. 2型糖尿病患者血清碱性磷酸酶与血脂及胰岛素抵抗的相关性分析[J]. 中国乡村医药, 2013, 20(19): 23-25.
https://doi.org/10.19542/j.cnki.1006-5180.2013.19.012
[16] 肖婷, 淦勤, 唐震宇, 黄小红. 碱性磷酸酶与脑小血管病患者认知功能的相关性研究碱性磷酸酶与脑小血管病患者认知功能的相关性研究[J]. 江西医药, 2022, 57(8): 907-911.
[17] Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group (2017) Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 Clinical Prac-tice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney International Supplements, 7, 1-59.
https://doi.org/10.1016/j.kisu.2017.04.001
[18] Massy, Z. and Drueke, T. (2017) Adynamic Bone Disease Is a Predominant Bone Pattern in Early Stages of Chronic Kidney Disease. Journal of Nephrology, 30, 629-634.
https://doi.org/10.1007/s40620-017-0397-7
[19] 华青, 张敏芳, 李璐瑶. 骨特异性碱性磷酸酶在慢性肾脏病矿物质与骨代谢紊乱中的研究进展[J]. 中国中西医结合肾病杂志, 2018, 19(7): 647-649.
[20] Delanaye, P, Souber-bielle, J.-C., Lafage-Proust, M.-H., Jean, G. and Cavalier, E. (2014) Can We Use Circulating Biomarkers to Monitor Bone Turnover in CKD Haemodialysis Patients? Hypotheses and Facts. Nephrology Dialysis Transplantation, 29, 997-1004.
https://doi.org/10.1093/ndt/gft275
[21] Bervoets, A.R.J., et al. (2003) Useful Biochemical Markers for Diagnosing Renal Osteodystrophy in Predialysis End- Stage Renal Failure Patients. American Journal of Kidney Dis-eases, 41, 997-1007.
https://doi.org/10.1016/S0272-6386(03)00197-5
[22] Kellett, K.A., Williams, J., Vardy, E.R., Smith, A.D. and Hooper, N.M. (2011) Plasma Alkaline Phosphatase is Elevated in Alzheimer’s Disease and Inversely Correlates with Cognitive Function. International Journal of Molecular Epidemiology and Genetics, 2, 114-121.
[23] Brichacek, A.L. and Brown, C.M. (2019) Alkaline Phosphatase: A Potential Biomarker for Stroke and Implications for Treatment. Meta-bolic Brain Disease, 34, 3-19.
https://doi.org/10.1007/s11011-018-0322-3
[24] Wardlaw, J.M., Smith, C. and Dichgans, M. (2013) Mechanisms of Sporadic Cerebral Small Vessel Disease: Insights from Neuroimaging. The Lancet Neurology, 12, 483-497.
https://doi.org/10.1016/S1474-4422(13)70060-7
[25] Wardlaw, J.M., et al. (2013) Neu-roimaging Standards for Research into Small Vessel Disease and Its Contribution to Ageing and Neurodegeneration. The Lancet Neurology, 12, 822-838.
https://doi.org/10.1016/S1474-4422(13)70124-8
[26] 张兵, 董瑞芳, 郄新稳, 田爽, 张超. 脑梗死合并缺血性脑白质病变患者危险因素的分析[J]中华老年心脑血管病杂志, 2017, 19(1): 67-69.
[27] Lee, H.-B., et al. (2015) Association between Serum Alkaline Phosphatase Level and Cerebral Small Vessel Disease. PLOS ONE, 10, e0143355.
https://doi.org/10.1371/journal.pone.0143355
[28] Langer, D., Ikehara, Y., Takebayashi, H., Hawkes, R. and Zimmermann, H. (2008) The Ectonucleotidases Alkaline Phosphatase and Nucleoside Triphosphate Diphosphohydrolase 2 Are Associated with Subsets of Progenitor Cell Populations in the Mouse Embry-onic, Postnatal and Adult Neurogenic Zones. Neuroscience, 150, 863-879.
https://doi.org/10.1016/j.neuroscience.2007.07.064
[29] Vardy, E.R.L.C., Kellett, K.A.B., Cocklin, S.L. and Hoop-er, N.M. (2012) Alkaline Phosphatase Is Increased in Both Brain and Plasma in Alzheimer’s Disease. Neurodegenera-tive Diseases, 9, 31-37.
https://doi.org/10.1159/000329722
[30] 吴有丽, 沈春子, 周霞, 张宏, 游孟哲, 朱小群, 孙中武. 皮质下缺血性血管病患者血清碱性磷酸酶变化及其对认知功能的影响[J]. 中华神经科杂志, 2016, 49(11): 827-832.
[31] Li, J.-W., Xu, C., Fan, Y., Wang, Y. and Xiao, Y.-B. (2014) Can Serum Levels of Alkaline Phosphatase and Phosphate Predict Cardiovascular Diseases and Total Mortality in Individuals with Preserved Renal Function? A Systemic Review and Meta-Analysis. PLOS ONE, 9, e102276.
https://doi.org/10.1371/journal.pone.0102276
[32] Kunutsor, S.K., et al. (2017) Serum Alkaline Phosphatase and Risk of Incident Cardiovascular Disease: Interrelationship with High Sensitivity C-Reactive Protein. PLOS ONE, 10, e0132822.
https://doi.org/10.1371/journal.pone.0132822
[33] Libby, P., Ridker, P. and Hansson, G. (2011) Progress and Challenges in Translating the Biology of Atherosclerosis. Nature, 473, 317-325.
https://doi.org/10.1038/nature10146
[34] Ndrepepa, G., et al. (2017) Prognostic Value of Alkaline Phosphatase in Patients with Acute Coronary Syndromes. Clinical Biochemistry, 50, 828-834.
https://doi.org/10.1016/j.clinbiochem.2017.05.020
[35] Pattanshetty, D.J., Cook, D., et al. (2017) Heart Failure Pa-tients with Reduced Ejection Fraction Have Higher Prevalence of Cognitive Impairment Despite Normal MMSE. Journal of Cardiac Failure, 23, S68.
[36] 刘佳月, 冯玉宝. 心血管疾病与认知功能障碍筛查的研究进展[J]. 中国社区医师, 2022, 38(6): 7-9.
[37] Hung, H.-Y., et al. (2017) Preoperative Alkaline Phosphatase Elevation Was Associated with Poor Survival in Colorectal Cancer Patients. International Journal of Colorectal Disease, 32, 1775-1778.
https://doi.org/10.1007/s00384-017-2907-4
[38] Wei, X.-L., et al. (2016) The Predictive Value of Alkaline Phos-phatase and Lactate Dehydrogenase for Overall Survival in Patients with Esophageal Squamous Cell Carcinoma. Tumour Biology, 37, 1879-1887.
https://doi.org/10.1007/s13277-015-3851-y
[39] Xu, X.-S., et al. (2014) Model Based on γ-Glutamyltransferase and Alkaline Phosphatase for Hepatocellular Carcinoma Prognosis. World Journal of Gastroenterology, 20, 10944-10952.
https://doi.org/10.3748/wjg.v20.i31.10944
[40] Li, G., et al. (2012) Increased Pretreatment Levels of Serum LDH and ALP as Poor Prognostic Factors for Nasopharyngeal Carcinoma. Chinese Journal of Cancer, 31, 197-206.
https://doi.org/10.5732/cjc.011.10283
[41] Faloppi, L., et al. (2015) The Value of Lactate Dehydrogenase Serum Levels as a Prognostic and Predictive Factor for Advanced Pancreatic Cancer Patients Receiving Sorafenib. On-cotarget, 6, 35087-35094.
https://doi.org/10.18632/oncotarget.5197
[42] Kotb, M.G., et al. (2019) Chemotherapy-Induced Cognitive Impair-ment in Hematological Malignancies. The Egyptian Journal of Neurology, Psychiatry and Neurosurgery, 55, Article No. 56.
https://doi.org/10.1186/s41983-019-0104-9